Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

CervoMed Publishes Results From AscenD-LB Phase 2a Trial Evaluating Treatment Of Neflamapimod In Dementia With Lewy Bodies

Author: Benzinga Newsdesk | February 12, 2024 09:08am

-Integrated summary of all previously published Phase 2a clinical results, together with the first peer reviewed publication of EEG and MRI results, substantially derisk the ongoing RewinD-LB Phase 2b trial of neflamapimod in dementia with Lewy bodies -

 

-RewinD-LB trial remains on track to complete enrollment in the first half of 2024 and report primary efficacy results in the second half of 2024-

Posted In: CRVO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist